StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to support seamless human pluripotent stem cell culture—from iPSC establishment through expansion, and from research to clinical manufacturing. Its simplified one-bottle formulation streamlines process development while reducing workflow complexity and contamination risk.

In rigorous testing - StemFit Basic04CT demonstrated improved workflow efficiency, enhanced ease of adoption and the lowest cost per well compared to other popular xeno-free stem cell culture products.

Dr Philipp Boder – Stem cell products manager at Amsbio commented  “One of the biggest concerns when changing hPSC media is disrupting an established workflow. What stood out to me in the new Basic04CT data is how straightforward the transition from another media can be – with no adaptation step, no change to substrate or passaging conditions, and comparable expansion across three passages. That removes an important practical barrier for labs considering a change of medium.”

For further information on StemFit™ Basic04CT please visit https://www.amsbio.com/stemfit-stem-cell-culture/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

StemFit™ Basic04CT is the proven ‘go to’ medium for use in large-scale production of stem cells. The manufacturing and quality control of this product are managed in strict accordance with GMP standards in a certified ISO 13485 facility. All bottles of StemFit™ Basic04CT come provided with a certificate of analysis and supporting quality and manufacturing documentation is available for translational and clinical applications.

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem cell platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.